Drug
Sporanox
Sporanox is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
1
50%
Ph phase_1
1
50%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(2)
Detailed Status
Completed2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (50.0%)
Phase 41 (50.0%)
Trials by Status
completed2100%
Recent Activity
0 active trials
Showing 2 of 2
completedphase_4
Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg
NCT02621905
completedphase_1
Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects
NCT00805090
Clinical Trials (2)
Showing 2 of 2 trials
NCT02621905Phase 4
Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg
NCT00805090Phase 1
Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2